Kairos Pharma, Ltd. (NYSE American: KAPA) announced the presentation of preclinical data on its investigational compounds KROS 101 and KROS 401 at the American Association for Cancer Research Immuno-Oncology (AACR IO) conference. The conference was held in Los Angeles from February 23-26, 2025.
The presented data highlighted positive preclinical outcomes for both compounds, supporting their potential as therapeutics for melanoma and glioblastoma. KROS 101 is a glucocorticoid-induced tumor necrosis factor receptor (GITR) agonist, and KROS 401 is also an investigational compound.
This presentation at a prominent scientific forum underscores Kairos Pharma's ongoing research and development efforts in oncology. The positive preclinical results contribute to the scientific foundation for these pipeline assets, which aim to address significant unmet medical needs in cancer treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.